login
Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

Gender does not affect periprocedural complications or long-term results of catheter ablation


Wednesday, 05 Oct 2011 10:50
Sonia Ammar
Sonia Ammar


A study presented at the European Heart Rhythm Association (EHRA)-Europace conference (26–29 June, Madrid) shows that gender does not affect periprocedural complications or outcomes of catheter ablation for paroxysmal atrial fibrillation.

 


Investigators Ammar et al found that there was no significant differences between men and women in the incidence of periprocedural stroke and transient ischaemic attack (1.8 vs. 0.9%; p=0.35), tamponade (3.6 vs. 1.5%; p=0.12), severe haematoma (1.8 vs. 0.9%; p=0.3), pseudoaneurysm (0.6 vs. 0.6%; p=ns) or pulmonary vein stenosis (0.6 vs. 0.3; p=ns). Additionally, after a mean follow-up of 3.4±2.7 years, 51% of women and 55% of men were free from atrial arrhythmias without antiarrhythmic drugs (p=0.34).

 

The results of the new study are in contrast to previous studies, which have shown that women have more frequently persistent atrial fibrillation, complications and procedural failures than men. However, the lead investigator of the new study, Sonia Ammar, German Heart Center, Hospital rechts der Isar at the Technical University of Munich, said that her study may have had a more homogeneous population than had previous studies (which possibly explained why no differences in outcomes were observed between men and women). She explained that in her study, the duration of atrial fibrillation before ablation was about six years in both men and women and, unlike other studies, women were not referred later for catheter ablation despite being significantly older than men (61±9 years vs. 55±10 years). “In regard to acute complications, there was a tendency toward more tamponades in women without a statistical difference. It is important to say that we reported our experience [of catheter ablation] since 1998. In the early years, complications of catheter ablation for atrial fibrillation were more frequent. In the last few years, we had an incidence of tamponades of less than 1% in paroxysmal atrial fibrillation ablation. Therefore, the difference is disappearing.” According to Ammar, some specificities of the German population in the study may also have affected the result.

 

The women in her study, as well as being older, had a higher CHADS2 (Congestive heart failure, hypertension, age ≥75 years, and prior stroke) score but this baseline characteristic did not appear to significantly increase the incidence of stroke in women compared with men (2.4% vs. 3.5%). “Eighty seven per cent of strokes occurred in patients with atrial fibrillation recurrence and/or no adequate oral anticoagulation. Atrial fibrillation ablation seems to modify the course of the disease and the rate of stroke, particularly in women.”

 

Although gender does not appear to have a significant effect, according to this study at least, on the outcome of catheter ablation, it does significantly influence the pathophysiology, epidemiology, and clinical presentation of many cardiac arrhythmias. Ammar said: “Women have significantly longer QT intervals than men, despite having higher heart rates. In contrast, men have a higher incidence of atrial fibrillation, Brugada syndrome, early repolarisation syndrome and sudden death compared with women.” Additionally, as women have a greater risk of drug-induced QT prolongation, antiarrhythmic drugs have to be “prescribed very carefully” in women. Ammar concluded: “Differences in gender hormones may explain some of these findings, but the reasons for these gender differences are not completely understood.” 




Add New Comment

Related Items


Most popular


“We all need the strength” to challenge unacceptable behaviour
Thursday, 20 Aug 2015
The editors of Annals of Internal Medicine have called for doctors to confront colleagues who act in a disrespectful manner towards patients after an anonymous essay in the journal highlighted ... “We all need the strength” to challenge unacceptable behaviour

New stem cell delivery method shows promise for treating end stage heart failure
Monday, 27 Jul 2015
A new clinical trial to test how a high dose of stem cells delivered via a method called retrograde coronary sinus infusion affects end stage heart failure patients is showing promising results. New stem cell delivery method shows promise for treating end stage heart failure

First participants enrolled in dabigatran study of AF patients undergoing PCI
Wednesday, 29 Jul 2015
Boehringer Ingelheim has announced that the first US patients have been enrolled in its international clinical trial—RE-DUAL PCI, which is evaluating the efficacy and safety of dabigatran in patients ... First participants enrolled in dabigatran study of AF patients undergoing PCI

Features


New trial to explore oral anticoagulation benefit in patients with atrial high rate episodes
Monday, 03 Aug 2015
AFNET and the ESC are initiating a new trial (NOAH – AFNET 6) investigating whether patients without diagnosed atrial fibrillation who present with atrial high rate episodes benefit from oral ... New trial to explore oral anticoagulation benefit in patients with atrial high rate episodes

Safety, accuracy and validation of medical smartphone applications
Tuesday, 28 Jul 2015
The use of mobile smartphones and tablets that run applications (apps) to function as clinical examination tools, reference databases, technique guides, or medical calculators is today a reality in ... Safety, accuracy and validation of medical smartphone applications

Profiles


Cecilia Linde
Monday, 22 Jun 2015
Cecilia Linde speaks to Cardiac Rhythm News about her work on a research platform for new onset ... Cecilia Linde

Michael Gold
Wednesday, 03 Jun 2015
William Gold spoke to Cardiac Rhythm News about his involvement in various clinical trials, his ... Michael Gold

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions